Tags Posts tagged with "list of marijuana stocks"

list of marijuana stocks


The Canadian stock market was closed for Victoria Day yesterday and today, three marijuana stocks reported several significant developments. We have highlighted these developments below to help you focus on important trends sweeping the industry.

New Cannabis IPO to Raise $50+ Million

One of newest and most differentiated Canadian cannabis producers, Cannabis Wheaton (CBW.V: TSX Venture) (KWFLF) announced a $50 million private placement and engaged a syndicate of agents co-led by Eight Capital and Canaccord Genuity.

The firm is selling special warrants and convertible debenture units and will use the net proceeds for general corporate purposes, for the financing of its streaming partners pursuant its streaming agreements, and for general and administrative expenses.

Cannabis Wheaton is off to a great start after the company reported that MMCAP International Inc. SPC intends to subscribe for up to $20,000,000 of the offering. The offering is expected to occur on June 21st and the company granted the underwriters an over-allotment option which increases the offering to $57.5 million.

Cronos’ Breaks Ground on a Brand New 315,000 sq. ft. Facility

Today, Cronos Group’s (MJN.V: TSX Venture) (PRMCF) wholly-owned licensed producer, the Peace Naturals Project broke ground on a 315,000 sq. ft. expansion that includes a 286,000 sq. ft. production facility, a 28,000 sq. ft. greenhouse, and an additional 1,200 sq. ft. extraction lab.

Upon completion, the facility is expected to be the largest purpose-built indoor cannabis production facility in the world. The facility is expected to complete by November and fully operational by summer 2018. This expansion will bring Peace’s total estimated production capacity to 40,000 kg a year.

The facility is designed to GMP certification standards and will include:

  • An area for proprietary genetic breeding
  • Pharma lab for cannabinoid and terpene extraction, identification, and formulation
  • R&D space for analyzing metabolite enhancement and new lighting technologies
  • Tissue culture laboratory
  • Industrial-grade kitchen
  • Processing infrastructure that supports production from other facilities

Cronos is breaking ground on the greenhouse today and the facility will be used to collect data and implement advanced cultivation techniques that can be replicated at its other production facilities. The company’s extraction lab will augment capabilities in both purification and recombination of cannabinoid compounds to create innovative formulated products. The greenhouse and lab are expected by the end of the summer.

Aurora to Supply Resources to Support a Groundbreaking Legal Case

Today, the Canadians for Fair Access to Medical Marijuana (CFAMM) reported an investment by Aurora Cannabis (ACB.V) (ACBFF) that is of a different nature than its prior investments.

CFAMM announced that Aurora has committed financial and other resources to support Gordon Skinner’s defense in what might be a potentially precedent-setting medical cannabis insurance coverage case. CFAMM has been providing strategic support to Skinner and Aurora’s resources will ensure that Skinner can defend his case.

On January 30th, the Nova Scotia Human Rights Commission ruled that the Board of Trustees of the Canadian Elevator Industry Welfare Trust Fund committed discrimination by denying coverage for the medical cannabis Skinner uses to manage chronic pain and other conditions resulting from a work-related injury that left him permanently impaired. Following the decision, the Board of Trustees filed an appeal against Skinner and the Commission in the Nova Scotia Court of Appeal. The appeal has been set for October 2, 2017.

Founded in 2014, Canadians for Fair Access to Medical Marijuana (CFAMM) is a federal non-profit, patient-run organization dedicated to protecting and improving the rights of medical cannabis patients. CFAMM’s goal is to enable patients to obtain fair and safe access to medical cannabis with a special focus on affordability, including private and public insurance coverage.

We want to commend Aurora on its commitment to improving the cannabis industry and supporting patients in need. This decision may have a lasting impact on the sector and could change the landscape of the Canadian medical cannabis industry.


Disclaimer: Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. We may buy or sell additional shares of (KWFLF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 14198

Among the many segments of the marijuana industry that we cover, CBD has taken on a big role not only for its biotech-based applications but also for its uses outside of the health sciences sector. And with the growth that the market as a whole could be set to see, CBD companies are definitely in the spotlight for the foreseeable future.

One Marijuana Stock that we’ve been reporting on since late last year has been Ubiquitech Software Corp (UBQU).  Now don’t let the name fool you, this company, through its subsidiary HempLife Today™ is breaking barriers with its CBD brand while also hitting major milestones over the last year.  What could be best of all is that 2017 could already have the stage set for yet another record setting period in (UBQU)’s company history.

Earlier this morning the company put out preliminary guidance on what it is anticipating to be a banner year ahead.  According to the release, the company anticipates that revenues for the year ending November 30, 2017 will increase over 55% from $3,493,113, which was reported in the annual period ended November 30, 2016 to approximately $5,450,000.

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance; Anticipates 55% Year Over Year Increase To $5,450,000

“We are very pleased with the progress we have made and we will continue to do everything within our power to keep our company relevant and growing” said James Ballas, CEO “With the quality of our products, our marketing, customer support and satisfaction, and our dynamic thinking, we will continue this growth through 2017 and into 2018, which we are already planning big things for, and this is the thinking that will take our revenues to even higher gains as we continue. It’s a very exciting industry and we don’t plan to stop until the CannazALL brand is a household word.”

(UBQU) is no stranger to growth.  If you’re just pulling up the company’s other headlines, you’ll already notice major strides being made on the product end. Toward the beginning of the year, the company announced that it had concluded negotiations and reached an agreement to expand its hemp growing capabilities through an additional 140 acres of available hemp operations. They’ve also expanded their current product line to include brand new offerings.

But back to growth…Had this been a random company with its first press release in history, we might be a bit skeptical but (UBQU) has already proven its ability to run a multi-million dollar business that has managed to grow significantly just within the last year alone. On top of bullish guidance for the year ahead, (UBQU) is also coming off of a strong year and noticeable earnings growth.

Revenues for the last quarter increased to $1,225,015 and to $3,493,113 for the year. But what’s more is that net income increased over 700% from the previous year to $334,350 from $39,651 in 2015. First quarter guidance has already come in bullish on its own with the company expecting revenues for the quarter ended February 28, 2017 to increase over 50% from $697,640 in the first quarter of last year to approximately $1,050,000.

Of course this is just initial guidance and with the year ahead, nothing is set in stone. But one thing is certain and that based on the last releases from the company, (UBQU) has set itself on a growth trend.  So this bullish guidance could be shedding some light on what’s to come for this company in the very near term.

The opportunity for taking advantage of the growth that CBD is beginning to see, could be important to take into consideration.  We’ve previously written about this market and how it could be on a path for growth.  Figures estimate that the CBD market will grow to a $2.1 billion market in sales by 2020. That’s a 700% increase from 2016.  Think about this for a moment: (UBQU) is already growing and is expecting to continue this growth to the tune of 50+% for the year according to today’s announcement…this is all going to happen during a time where the CBD industry as a whole is also anticipating significant growth. Having already come off of a banner year, we think that preliminary guidance from the company would suggest that this is something to be paying close attention to moving into the coming weeks/months/quarters.

Again, you can access today’s (UBQU) news here:

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance; Anticipates 55% Year Over Year Increase To $5,450,000

Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. We may buy or sell additional shares of (UBQU) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here




0 1998

DENVER, CO–(Mar 23, 2017) – Ubiquitech Software Corp. ( OTC PINK : UBQU ), through its operating subsidiary HempLifeToday.com, is announcing fiscal year 2017 revenue guidance.

The company anticipates that revenues for the year ending November 30, 2017 will increase over 55% from $3,493,113 reported in the year ago period to approximately $5,450,000.

The company is basing this guidance on the strong internal first quarter numbers and the continuance of that trend during March of this year. The company continues to gain increased exposure of its HempLife Today product line, develop new and improved products, and spread the word regarding the benefits of CBD Hemp derived products available and sold through its proprietary CBD brand CannazALL.

The company expects to give updates on its full year guidance in the coming months. The company sells and markets its line of high quality products through its web portal www.HempLifeToday.com.

“We are very pleased with the progress we have made and we will continue to do everything within our power to keep our company relevant and growing,” said James Ballas, CEO. “With the quality of our products, our marketing, customer support and satisfaction, and our dynamic thinking, we will continue this growth through 2017 and into 2018, which we are already planning big things for, and this is the thinking that will take our revenues to even higher gains as we continue. It’s a very exciting industry and we don’t plan to stop until the CannazALL brand is a household word.”

“With the wide footprint we have on the Internet and the amount of industry content about us that is also growing, we have the ability to grow while also protecting revenue,” adds Tim Zorn, President. “This allows us to strategically spend advertising dollars where we get the best results and is why our cost per customer acquisition is down by over 90% since last year. Steady sales and profitability is what we always strive for.”

The Company wants shareholders to know that it is moving forward on all plans released in previous press from 3.09.2017. This update is to inform shareholders of company progress and to keep shareholders informed of said progress.

About Ubiquitech (HempLife Today™)
Ubiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, Direct Response (DRTV) Television, Radio, and traditional marketing, to drive traffic to the new and emerging multi-billion dollar industries like its subsidiary HempLifeToday.com™

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid, all offered @ www.HempLifeToday.com

This press release contains forward-looking statements. Words such as “expects”, “intends”, “believes”, and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

0 5840
Marijuana Stocks

Marijuana Stocks, especially Cannabis Companies with strong ties to Biotech have been increasingly front and center on Wall Street’s main stage.  Marijuana Stocks and the Cannabis-Biotech sector continue to evolve and grow into the mainstream powerhouse we know it can and will be. We have identified a small Cannabis-Biotech start up that deserves your attention.

InMed Pharmaceuticals (IMLFF) is a Vancouver-based pre-clinical trial Cannabis-Biotech company that has not only developed a proprietary cannabinoid manufacturing system yet in the process created a highly sought after database, which has mapped the different compounds of cannabinoids to the various diseases that it can address.

This cannabinoid database was designed by (IMLFF) to assist them in their investigative studies and has currently become a core asset as other Cannabis Biotech companies have come knocking on their door willing to offer a hefty sum for this information. Most medical marijuana processors are using THC and CBD because they are easy to extract in large quantities, however there are more than 90 diverse cannabinoid structures that (IMLFF) has plugged into its system. The bioinformatics algorithm has taken those different compounds and screens them against approved drugs, diseases and genetic properties of diseases. It then selects specific cannabinoids that might help regulate that particular disease.

InMed Pharmaceuticals (IMLFF) has created this database “tool” & is saving time and money in the drug research process. It has already helped (IMLFF) to identify two treatments for rare diseases. One for a rare children’s skin disease called epidermolysis bullosa (EB) that has no approved treatments and the other for glaucoma. Chief Executive Officer Eric Adams said, “It’s a very devastating disease and we found out in early testing that this set of cannabinoids treat the major symptoms of this disease giving them a tremendous amount of relief, but it may also reverse the disease, which is something no one has really talked about before.”

Startup Cannabis-Biotechs like InMed Pharmaceuticals (IMLFF) will continue to grow as Marijuana Stocks / Sector continues to evolve into mainstream markets.

0 11494
cbd stocks

List Of CBD Stocks To Watch

For a fairly new market, the Marijuana industry has been embracing unprecedented levels of growth over the past decade. The surge had every investor frantically logging in to their e-trade accounts trying to find the next big Marijuana stock. Although the previous focus of the medical companies was based on the harvesting of the THC component of Marijuana, many have recently discovered the true health benefits of Cannabidiol; a part of the plant that only holds its health benefits and not those that get you ‘high’.

cbd stocks

The recent deregulation and legalization patterns that every state has been following over the past decade are only a testament to how close the United States is to nation-wide legalization. In addition to the whopping 23 states who have already legalized marijuana, there are 15 other states that have legalized the sale of medicinal.

Marijuana businesses in Colorado, which voted to legalize the drug recreationally in 2012, reported about $1.1 billion in legal sales of medical and recreational marijuana and related products last year through the month of October, according to the tax data from the state’s Department of Revenue. That number easily tops the roughly $996 million in total marijuana revenue the state reported in 2015. With this has come an increase in awareness across the board and one of the hottest topics right now has been CBD.  Based on the attention the industry is getting, it seems fitting to highlight some of the most active CBD stocks to watch this year. Here are several CBD stocks on our own list:

Ubiquitech Software Corp (UBQU)

Ubiquitech Software Corp’s main subsidiary Hemplifetoday.com, focuses on the sale of CBD products through their network of International growers.

This week the company released earnings guidance for the quarter giving high expectations for year over year growth. Management is anticipating a 50% increase in revenue for the quarter compared to last year.

The company anticipates that revenues for the quarter ended February 28, 2017 will increase over 50% from $697,640 in the first quarter of last year to approximately $1,050,000. The revenue growth is due primarily to the continued acceptance and increased exposure of the HempLife Today™ product line.

“We are excited to show what we have achieved over the past few years,” said James Ballas, CEO, “and we pride ourselves on our process of delivering a superior product at a cost that makes our products available to the widest possible audience. Because, it is this process that makes our company continue to grow.”

This is in addition to the growth that the company has seen already. Earlier this year, UBQU announced its fourth quarter and fiscal year end 2016 financial results. Revenues for the quarter increased to $1,225,015 and to $3,493,113 for the year. Earnings increased 840% from the previous year to $334,350 from $39,651 in 2015. To date, the stock has jumped as high as $0.04 and is now trading in a channel nearly 50% higher than where it was trading at toward the beginning of the year. Considering the last two financial related announcements discussed noticeable growth, this could be the trend to watch for with this company in 2017.

Corbus pharma(CRBP)

Corbus Pharma actually has no direct engagement with medical or recreational marijuana sales. They are focused on developing a non-psychoactive synthetic drug that imitates the health benefits caused by the bodies reaction to CBD, Resunab. Currently in phase 3 testing, the drug is said to be release in 2019 and will be a huge driver for this $400-million cap company.

Over the last 3 months Corbus stock price has been experiencing volatile movements, dropping to 6.4 dollars in mid-February. However, the stock has been steadily increasing since. Corbus could be a good purchase because of its inelasticity to the stock prices of other marijuana stocks after possible government regulation. This offers a level of diversity which could prove to be extremely advantageous especially with the change of government in November.

mCig, Inc. (MCIG)

Since it was trading around 2 and a half cents in September, MCIG has seen highs of as much as $0.505.  The stock has been upholding a channel roughly between $0.30 and $0.40 for the last few weeks and multiple announcements show, in our opinion, that company’s focus on building shareholder value including triple digit sales growth, canceling 20 million shares  and converting another 60 million shares into preferred that also carry with it a 2 year lock up.  The company has also announced that it will be reporting on its “record financial growth numbers and cost basis investments; to include, Vapolution, VitaCBD, Omni Health (OTC PINK: OMHE,) Agri-Contractors, and other strategic partnerships.”

This week MCIG filed its 3rd Quarter financial reports showing significant growth for the company including:

  • Revenue increased 446% to $1,362,689 compared to $249,641
  • Gross profit increased 239% to $288,230 compared to $85,076
  • Expenses decreased 27% to $97,052 compared to $133,236
  • Cash and cash equivalents increased 422% to $420,888 compared to $80,542
  • Current assets increased 1,241% to $1,259,689 compared to $93,930

Cara Therapeutics(CARA)

Founded in 2004, Cara therapeutics was an interesting stock to watch over the past year. They are currently in the preclinical trials of creating a CBD compound that can be used for treating neuropathic and inflammatory pains, a market usually only tainted with opioids.

Despite their stock price drop over 62 percent in 2016, Cara has been steadily climbing since, in the first 2 months of 2017 the stock price managed to skyrocket by 186% ($9-$16.72). Their recent expansions into the pain-relief industry could become a huge catalyst for their growth, especially as the market starts to accept CBD as a healthier alternative to addictive opiate-based painkillers.

Advantis Corp. (ADVT)

We started watching Advantis Corp. (ADVT)  last summer. There’s enough going on here in our opinion to take notice of including the recent announcements that the company has taken steps to become a fully-reporting public company as well as launched distribution of topical cannabis roll-on and Tinctures to treat pain conditions. This also comes as the company has begun to further expand on its overall product offering so just like we cited at first “way back when” with Totally Hemp Crazy, we think that ADVT could be another company to follow during its infancy.  Since we picked back up on this, we’ve also watched as ADVT climbed from around $0.005 to highs of $0.035 during the last full week of February.

This week the company announced that it has received the first orders for Hemperor’s Club, Elixicure and Deltacure products from California’s largest medical marijuana delivery service, Speedweed. The delivery service has asked Advantis to participate as a Premiere Guest of Speedweed at the Cannabis Business Expo this week.

Insys therapeutics (INSY)

Insys therapeutics, is a specialty pharmaceutical company that has started their venture into the cannabis industry over the past year. Just recently the FDA green lit the pharmaceutical giants reformulation of the longest standing marijuana based medicine, marinol. Originally created by ABBvie incorporation, the reformulated medicine (Now syndros) is an effective and healthy way to treat millions of cancer patients who suffer from nausea from Chemotherapy sessions, Also doubling as a treatment for the lack of appetite in aids patients. According to studies done by Insys, Sydros is said to eventually generate peak annual sales of roughly 200 million dollars, only 20 million dollars less than their top selling opioid painkiller Subsys.

Although the stock price hit a trough in the middle of December of 2016 due to an ongoing court case, It a poised them for growth in the next year. While there still hasn’t been a definite outcome in the settlement of the cases, The Small-Cap pharmaceutical companies’ price has steadily been increasing since the incident. Their new change in management combined with their recent developments in the cancer relief industry might prove them to be an extremely interesting stock to watch in 2017.

Gw Pharma (GWPH)

Judging by the fact that you are reading this article, chances are that you have heard about the next stock, British medical marijuana giant GW pharma. Founded in 1998, The English pharmaceutical company has been specializing in creating CBD-based prescription medicines for their widespread international consumers. The company’s Key product is Sati vex, an oromucosal spray for the treatment of cancer pain, Multiple Sclerosis and neuropathic pain. Just recently, GW pharma submitted their request to formulate medicine Epidiolex, Created to treat the 2 million people who suffer from epilepsy in the united states. This vast consumer base has set projected peak annual sales from $300 million to $3 Billion. The main question at hand is whether they will be able to maintain this level of steady growth. Although the price had been stagnant, following a small decrease in price a month ago the stock has been steadily increasing, The true results will begin to shine as they begin to sell their breakthrough medicine, Epidiolex.

AbbVie (ABBV)

Best known for their “miracle” arthritis drug Humira (The top Selling drug in the world), their new developments into the CBD industry will prove to be something to monitor for the growth of this company’s market cap. Their latest cancer-relief medicine Venclexta, is projected to reap in at least 1.5 billion dollar’s worth of annual sales in the next year.

Like most companies in the Medicinal Marijuana industry, AbbVie faced a giant drop in stock price in November because of regulation skepticism as a result of the election of United States President Donald Trump. They still, however, continue to grow their revenue and earnings by double digit numbers, not to mention an attractive dividend yield of 4.2%. Collectively with their relatively cheap stock price and their recent advances into the CBD and autoimmune industries, this stock will be very interesting to watch in 2017.

AXIM Biotech (AXIM)

Axim Biotech recently announced their plans of improving their patent for the worlds first CBD chewing gum. The small-cap pharmaceutical company decided to take an interesting approach to the widespread intake of CBD for medication purposes. Furthering their customer-base, AXIM has engaged in new studies to test the benefits of cannchew from IBS patients to sclerosis patients, this increase consumer base will be a huge driver in their performance in 2018.

Despite their growth over the past 2 years, AXIM is still not a profitable company, closing out 2016 with $870,000, just shy of their $1.5 million debt. Their stock price spiked in mid January after this announcement at the JP Morgan Health Care Conference, the stock then fell down to 9 dollars thereafter. Their execution of their strategies over the next year will be the real facilitator of the outcome of the companies overall success.

HEMP incorporated (HEMP)

HEMP Inc, longer standing marijuana/CBD stocks on this list is set on becoming the market leader in the widespread distribution and use of hemp products in the world. Although their prime focus was the prevalent cultivation of hemp, HEMP Inc. has enacted new plans to build over 500 acres of farm land, made simply for the production of CBD products, due to its continuously widespread legal adaptation across the united states.

Due to their experience in the industry, their ventures will mostly be a product of their established market presence in our opinion. One thing to keep watch on are the fraud claims that have been filed against HEMP Inc. CEO, Bruce Perlowin. The stock price took a hit just days after President Trump’s secretary Spicer gave his remarks about the future of legal marijuana. Despite this temporary downfall, HEMP continues to stay the course, trading between $0.03 and $0.04 during early March.

Zynerba Pharmaceuticals (ZYNE)

Founded in 2007, Zynerba pharmaceuticals have developed a steady focus in commercializing the widespread use of synthetic cannabinoids through transdermal(skin) delivery. The company is currently studying their product ZYN001 which target Fibrositis and neuritis patients, two epidemics that generate over 6 million cases in the United States alone. The CBD is delivered through a patch that is intended for application to the back, arm and thigh.

In mid-January, Zynerba announced that they will be selling 2.8 million shares at a 25% discount of the original $22.4 in order to raise money for the phase 3 development of their products. The trajectory of this firm will most likely be based on how quickly they receive acceptance from the FDA (projected Q1 of 2018) and the overall performance of their new products on the market. As of today, The stock price has been steadily increasing and has actually reached its highest point on February 15th.

Obviously these are just a few of the CBD stocks to watch but will be a list that we’ll continue to monitor and if necessary update.  If you’ve just come to MarijuanaStocks.com, we’ve been covering the CBD industry specifically for the last few months considering its place in the legal arena.

Despite the recent negative reactions due to certain  statements made by the secretary of the White House we think the marijuana industry will continue to grow. The industry’s revenue increase in 2016 and the endless advantages green-states like Colorado have assumed since legalization are proof that Medicinal Marijuana is an industry that can provide great advantages.

The bright side in this is that traders can use these negative (government-caused) movements in the stock prices as methods to look at some of these stocks at lower levels. The recent medical findings in CBD research, have created an entire new sector to the Marijuana industry. Judging by its growth over the past 4 years, we think that this could prove to be one of the main drivers in its success.


Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 6 million restricted shares of Hemp, Inc. We may buy or sell additional shares of (HEMP, UBQU) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER.

    0 2330

    Over recent weeks we’ve been shedding more light on the hemp industry and why we see it as an important part of the bigger cannabis space.  Marijuana Stocks, the Wolf of Weed Street and Cheryl Shuman have been working closely with FBEC Worldwide to help develop the first branded hemp infused energy drink for FBEC called the “Wolf Shot Hemp Energy.” The product launch is slated for August 1 and buzz has grown quickly.  Friday FBEC Worldwide was highlighted in an article on TheStreet.com, which focused specifically on the Hemp industry, what it is, why it’s important, and why investors should be paying much more attention to it now more than ever:

    “Hemp Won’t Get You High, But Could Boost Your Portfolio Sooner Than You Think”

    The article discusses the differences between hemp and marijuana citing that though they both are derived from the same type of cannabis plant, their uses couldn’t be more different. Major health benefits from hemp include higher levels of easily digestible protein, longer sustained levels of energy, improved mental focus and even reduction in cardiovascular disease.  The biggest benefit is that though it is limited to growing in the US, using and selling products that have it is not.  Highlighting FBEC Worldwide as a viable option for taking advantage of the growth that this space could see in both short and long terms adds much more legitimacy to the company and shows the true differences between companies planning to do something and companies actually doing it like FBEC Worldwide is; now 3 weeks away from initial product launch.

    Read the full article HERE

    0 1727

    While screening for drugs is not new, the legalization of recreational cannabis in states such as Washington, Oregon, Alaska, and Colorado has added a question mark for some workers and people trying to find employment. However recreational marijuana smokers may be held responsible and not allowed the use of cannabis to effect their work lives. Should they still be worried about company drug policies? Marijuana used on a weekend does not mean cannabis was used at work though present drug testing can’t tell the difference.

    A recent issue has been the strict way of drug screening and drug use policies in the work environment and how they possibly could be eliminating great prospective hires’ consideration, especially concerning zero tolerance policies that sometimes extend into the past. For instance, the CIA asks about the use of cannabis going as far back as 12 months prior to filling out an application while the FBI and some law enforcement agencies look as far back as 3 years.

    A zero tolerance system, something very common among employers thought America, automatically eliminates various prospects to hire who are fresh out of college and looking for employment. This is really causing an issue in states where recreational cannabis is currently legal. The concern is that zero tolerance policies are often identical to the federal Drug-Free Workplace Act of 1988 and the Drug-Free Schools & Communities Act Amendments of 1989, which are not entirely unreasonable but are starting to create an issue with state laws that are changing the federal stance on cannabis.


    Peter Cappelli, a professor of management at The Wharton School, looks at these policies as a hindrance to employers as well as the prospective employees, yet he does not feel they will be changed anytime in the near future, “My guess is that [companies will] just continue to suffer from it, that it’s harder to hire people, because it’s politically too difficult to explain.”

      0 2059

      Colorado-Based Blue Line Protection Group has opened a subsidiary to allow the company that ability to handle financial services for Marijuana companies. These include licensing and bookkeeping. Blue Line’s CFO, Patrick Deparini told the New York Daily News, “Our goal is to streamline and simplify the day-to-day bookkeeping duties these businesses face. By doing so, we reduce our clients’ operating costs, help ensure their compliance with the myriad local, state and federal regulations, and provide them with peace of mind with our guarantee of audit protection services.”

      Blue Line’s new business, Blue Line Advisory Services is pushing forward to become a legal liaison for the budding marijuana industry, which to this point has been mainly a “cash-only business”. Banks are still hesitant to take money from cannabusinesses. Despite this fact, Uncle Sam still needs his cut.

      In Colorado, the Denver IRS has set up a separate, Cash-only line and even though growing cannabis is deductible under the federal tax law, selling it is not and ends up putting business owners into higher tax brackets!

      For Blue Line Protection, their new finance focused business, Blue Line Advisory will look to become an integral part of the financial landscape of this expanding marijuana industry.


      Read More at New York Daily News

      Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

      We are your #1 source for all things Marijuana Stocks, Subscribe Below!

      Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
      Ad Placements